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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Spinal muscular atrophy (SMA) is a neuromuscular disorder of childhood.
• Riluzole is an anti-excitatory agent recommended for the treatment of
amyotrophic lateral sclerosis (ALS).
• Riluzole pharmacokinetics are well documented in patients with ALS.
WHAT THIS STUDY ADDS
• Riluzole pharmacokinetics have never documented in patients with SMA.
• This study showed that the administration of 50 mg riluzole once a day to
patients with SMA leads to total riluzole daily exposure comparable with that
obtained after the administration of 50 mg twice a day in healthy volunteers or
ALS patients.
AIMS
The objective of the present study was to assess the pharmacokinetics of riluzole
in patients with spinal muscular atrophy (SMA).
METHODS
Fourteen patients were enrolled in an open-label, nonrandomized and repeat-dose
pharmacokinetic study. All participants were assigned to receive 50 mg riluzole
orally for 5 days. Riluzole plasma concentrations were determined from samples
obtained at day 5.
RESULTS
The pharmacokinetic analysis demonstrated that a dose of 50 mg once a day was
sufficient to obtain a daily total exposure [AUC(0,24 h) = 2257 ng ml-1 h] which
was comparable with results obtained in adult healthy volunteers or ALS patients
in whom a dose of 50 mg twice a day is recommended. The pharmacokinetic
simulation demonstrated that the administration of 50 mg twice a day could result
in higher concentrations, hence reduced safety margin.
CONCLUSION
The dose of 50 mg once a day was chosen for the clinical trial evaluating the
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